Baidu
map

Lab Invest:糖尿病视网膜病变中的血管变化

2019-05-31 不详 网络

加利福尼亚大学圣巴巴拉分校干细胞生物学与工程中心的Toh H等人近日在Lab Invest杂志上发表了一篇研究论文,他们利用动物模型,研究了糖尿病过程中视网膜细胞的动态变化过程。

加利福尼亚大学圣巴巴拉分校干细胞生物学与工程中心的Toh H等人近日在Lab Invest杂志上发表了一篇研究论文,他们利用动物模型,研究了糖尿病过程中视网膜细胞的动态变化过程。

糖尿病性视网膜病变是糖尿病最常见的微血管并发症,并且是失明的主要原因。但由于缺乏准确的动物模型,对疾病发病机理的理解还不是很清楚。在这里,他们探讨了对碳水化合物敏感的2型糖尿病模型尼罗河大鼠(Arvicanthis niloticus)的视网膜细胞的动态变化。

尼罗大鼠的糖尿病模型研究显示,早期视网膜变化主要包括毛细血管的增加和周围细胞的丢失,其与糖尿病的持续时间呈现线性相关特征。这些血管变化发生在小胶质细胞浸润的情况下,但有趣的是并没有视网膜神经节细胞损失。在长时间的遭受糖尿病后,尼罗大鼠还表现出在人类病症中常见的一系列视网膜病变,包括血管渗漏、非灌注毛细血管和新血管的形成。

他们的研究记录了糖尿病尼罗大鼠视网膜病变的程度和发生发展过程,以及观察到的与人类糖尿病视网膜病变非常相似的特征。这表明该模型在鉴定新的治疗策略方面具有重要价值。

原文出处:

Toh, H., et al., Vascular changes in diabetic retinopathy-a longitudinal study in the Nile rat. Lab Invest, 2019.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2051388, encodeId=56ab205138892, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Nov 13 10:34:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270197, encodeId=823d12e0197f2, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sun Jun 02 14:34:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413988, encodeId=8e2b14139885b, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Sun Jun 02 14:34:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042482, encodeId=878e10424823b, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Jun 01 02:34:00 CST 2019, time=2019-06-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2051388, encodeId=56ab205138892, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Nov 13 10:34:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270197, encodeId=823d12e0197f2, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sun Jun 02 14:34:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413988, encodeId=8e2b14139885b, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Sun Jun 02 14:34:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042482, encodeId=878e10424823b, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Jun 01 02:34:00 CST 2019, time=2019-06-01, status=1, ipAttribution=)]
    2019-06-02 zutt
  3. [GetPortalCommentsPageByObjectIdResponse(id=2051388, encodeId=56ab205138892, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Nov 13 10:34:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270197, encodeId=823d12e0197f2, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sun Jun 02 14:34:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413988, encodeId=8e2b14139885b, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Sun Jun 02 14:34:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042482, encodeId=878e10424823b, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Jun 01 02:34:00 CST 2019, time=2019-06-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2051388, encodeId=56ab205138892, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Nov 13 10:34:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270197, encodeId=823d12e0197f2, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sun Jun 02 14:34:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413988, encodeId=8e2b14139885b, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Sun Jun 02 14:34:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042482, encodeId=878e10424823b, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Jun 01 02:34:00 CST 2019, time=2019-06-01, status=1, ipAttribution=)]
    2019-06-01 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

Eur Arch Otorhinolaryngol:环孢霉素鼻喷雾剂在过敏性鼻炎中的效用评估

最近,有研究人员进行了旨在表明是否环孢霉素在小牛血清诱导的过敏性鼻炎小鼠模型中具有抗过敏作用的研究。研究包括了54只小鼠,并被分成6个相同数目的小组。第1组为阴性对照组,没有进行诱导性的过敏性鼻炎;第2小组为阳性对照组,进行了诱导性的过敏性鼻炎但是没有进行治疗。剩下的4个小组在进行过敏性鼻炎诱导之后分别接受了0.05%、0.1%、0.2%浓度剂量的鼻内环孢霉素治疗或者鼻类固醇治疗。在生化检查中,研

2017 疾病特异性模型研究及应用研讨会

目前人疾病特异性模型研究的最新态势之一是利用病患自身的病变细胞,通过重编程,构建特异性的疾病iPSCs类器官模型,它具有三维立体结构,相比二维细胞,可更好地反映真实疾病状况,缩短药物研发时间和促进疾病机理研究,同时避免动物试验带来的伦理问题。

Gastroenterology:Barrett食管患者疾病进展评估模型

研究认为,男性、吸烟、Barrett食管长度以及基线低度异型增生与Barrett食管患者疾病进展相关

Baidu
map
Baidu
map
Baidu
map